This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McLachlan, S. M. Articles by Rapoport, B. Search for Related Content PubMed PubMed Citation Articles by McLachlan, S. M. Articles by Rapoport, B.

Insight into Graves’ Hyperthyroidism from Animal Models

Autoimmune Disease Unit (S.M.M., B.R.), Cedars-Sinai Research Institute and University of California Los Angeles School of Medicine, Los Angeles, California 90048; and Department of Medical Gene Technology (Y.N.), Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-85001, Japan

Correspondence: Address all correspondence and requests for reprints to: Sandra M. McLachlan, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite B-131, Los Angeles, California 90048. E-mail: mclachlans{at}cshs.org

Graves’ hyperthyroidism can be induced in mice or hamsters by novel approaches, namely injecting cells expressing the TSH receptor (TSHR) or vaccination with TSHR-DNA in plasmid or adenoviral vectors. These models provide unique insight into several aspects of Graves’ disease: 1) manipulating immunity toward Th1 or Th2 cytokines enhances or suppresses hyperthyroidism in different models, perhaps reflecting human disease heterogeneity; 2) the role of TSHR cleavage and A subunit shedding in immunity leading to thyroid-stimulating antibodies (TSAbs); and 3) epitope spreading away from TSAbs and toward TSH-blocking antibodies in association with increased TSHR antibody titers (as in rare hypothyroid patients). Major developments from the models include the isolation of high-affinity monoclonal TSAbs and analysis of antigen presentation, T cells, and immune tolerance to the TSHR. Studies of inbred mouse strains emphasize the contribution of non-MHC vs. MHC genes, as in humans, supporting the relevance of the models to human disease. Moreover, other findings suggest that the development of Graves’ disease is affected by environmental factors, including infectious pathogens, regardless of modifications in the Th1/Th2 balance. Finally, developing immunospecific forms of therapy for Graves’ disease will require painstaking dissection of immune recognition and responses to the TSHR.

This article has been cited by other articles:

				A. Fierabracci, M. A. Puglisi, L. Giuliani, S. Mattarocci, and M. Gallinella-Muzi Identification of an adult stem/progenitor cell-like population in the human thyroid J. Endocrinol., September 1, 2008; 198(3): 471 - 487. [Abstract] [Full Text] [PDF]

				E. Borgogni, E. Sarchielli, M. Sottili, V. Santarlasci, L. Cosmi, S. Gelmini, A. Lombardi, G. Cantini, G. Perigli, M. Luconi, et al. Elocalcitol Inhibits Inflammatory Responses in Human Thyroid Cells and T Cells Endocrinology, July 1, 2008; 149(7): 3626 - 3634. [Abstract] [Full Text] [PDF]

				S. M. McLachlan, H. A. Aliesky, P. N. Pichurin, C.-R. Chen, R. W. Williams, and B. Rapoport Shared and Unique Susceptibility Genes in a Mouse Model of Graves' Disease Determined in BXH and CXB Recombinant Inbred Mice Endocrinology, April 1, 2008; 149(4): 2001 - 2009. [Abstract] [Full Text] [PDF]

				Y. Inukai, A. Momobayashi, N. Sugawara, and Y. Aso Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease Eur. J. Endocrinol., June 1, 2007; 156(6): 623 - 630. [Abstract] [Full Text] [PDF]

				H. A. Aliesky, P. N. Pichurin, C.-R. Chen, R. W. Williams, B. Rapoport, and S. M. McLachlan Probing the Genetic Basis for Thyrotropin Receptor Antibodies and Hyperthyroidism in Immunized CXB Recombinant Inbred Mice Endocrinology, June 1, 2006; 147(6): 2789 - 2800. [Abstract] [Full Text] [PDF]

				O. Saitoh and Y. Nagayama Regulation of Graves' Hyperthyroidism with Naturally Occurring CD4+CD25+ Regulatory T Cells in a Mouse Model Endocrinology, May 1, 2006; 147(5): 2417 - 2422. [Abstract] [Full Text] [PDF]

				H. Jaschke, S. Neumann, S. Moore, C. J. Thomas, A.-O. Colson, S. Costanzi, G. Kleinau, J.-K. Jiang, R. Paschke, B. M. Raaka, et al. A Low Molecular Weight Agonist Signals by Binding to the Transmembrane Domain of Thyroid-stimulating Hormone Receptor (TSHR) and Luteinizing Hormone/Chorionic Gonadotropin Receptor (LHCGR) J. Biol. Chem., April 14, 2006; 281(15): 9841 - 9844. [Abstract] [Full Text] [PDF]

				P. N. Pichurin, C.-R. Chen, G. D. Chazenbalk, H. Aliesky, N. Pham, B. Rapoport, and S. M. McLachlan Targeted Expression of the Human Thyrotropin Receptor A-Subunit to the Mouse Thyroid: Insight into Overcoming the Lack of Response to A-Subunit Adenovirus Immunization J. Immunol., January 1, 2006; 176(1): 668 - 676. [Abstract] [Full Text] [PDF]